Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 17, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Oral Mucositis Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight

New York, USA, April 17, 2025 (GLOBE NEWSWIRE) -- Oral Mucositis Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight The growth of the oral mucositis market is...
December 26, 2019 08:00 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals: Patient Screening for Phase 1 Trial of Oral Brilacidin in Ulcerative Colitis Program On Track for Early January

Patient screening positions Company for completion of a short clinical trialSignificant market demand for oral drugs in Inflammatory Bowel DiseaseBusiness development meetings scheduled during 2020...
November 13, 2019 08:30 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals: Oral Cancer on the Rise; Company Offers Perspectives on Opportunity of Brilacidin for the Prevention of Oral Mucositis

Oral cancer incidence increasing worldwide due to spread of human papillomavirus (HPV), Oral SexMillions of patients worldwide suffer from treatment-induced Oral Mucositis (OM)Existing OM therapies...
August 22, 2019 10:38 ET | Source: Medifirst Solutions

Medifirst Solutions Provides Company Update for Its Oral Mucositis Treatment Studies

Freehold, NJ, Aug. 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA...
May 01, 2019 08:00 ET | Source: IntelGenx Technologies Corp.

IntelGenx Announces Issuance of Second U.S. Patent for Topical Oral Film Technology

SAINT LAURENT, Quebec, May 01, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that the United States Patent...
April 21, 2016 08:00 ET | Source: R-PHARM US, LLC

R-PHARM US Expands its Oncology Asset Portfolio with the Exclusive License and Distribution Rights to episil® in the United States

PRINCETON, N.J., April 21, 2016 (GLOBE NEWSWIRE) -- R-PHARM US today announced it has obtained the exclusive license and distribution rights to commercialize episil® oral liquid in the U.S....
May 07, 2015 16:42 ET | Source: Sucampo Pharmaceuticals Inc

FDA Grants Fast Track Designation to Sucampo's Cobiprostone for Oral Mucositis

BETHESDA, Md., May 7, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA)...
August 07, 2013 20:02 ET | Source: Sucampo Pharmaceuticals Inc

Sucampo Announces Positive Top-Line Results in Phase 1a Trials of Cobiprostone and SPI-3608

BETHESDA, Md., Aug. 7, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) (Sucampo) today announced the positive top-line results of two recently completed clinical trials, a Phase...